The primate EAE model points at EBV-infected B cells as a preferential therapy target in multiple sclerosis

Frontiers in Immunology

Volumn 4, Issue JUN, 2013, Pages

  'T Hart, Bert A ^a,b,c   Jagessar, S Anwar ^a,b   Haanstra, Krista ^a   Verschoor, Ernst ^a   Laman, Jon D ^b   Kap, Yolanda S ^a,b  

^a BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

B cell; EAE; EBV; Immunotherapy; MS; Non human primate; T cell

Indexed keywords

ALEMTUZUMAB; ATACICEPT; AUTOANTIBODY; CD20 ANTIGEN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NATALIZUMAB; OFATUMUMAB; RITUXIMAB; USTEKINUMAB;

B LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOMEGALOVIRUS INFECTION; CYTOTOXICITY; DISEASE COURSE; EPSTEIN BARR VIRUS INFECTION; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; HUMAN; IMMUNOPATHOGENESIS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; NONHUMAN; PRIMATE MODEL; REVIEW; SIGNAL TRANSDUCTION; TRANSGENIC MOUSE;

EID: 84882285039     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2013.00145     Document Type: Review

References (77)

1. Ascherio, A., and Munger, K. L. (2007). Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288-299. doi:10.1002/ana.21117
2. Axthelm, M. K., Bourdette, D. N., Marracci, G. H., Su, W., Mullaney, E. T., Manoharan, M., et al. (2011). Japanese macaque encephalomyelitis: a spontaneous multiple sclerosis-like disease in a nonhuman primate. Ann. Neurol. 70, 362-373. doi:10.1002/ana.22449
3. Barun, B., and Bar-Or, A. (2012). Treatment of multiple sclerosis with Anti-CD20 antibodies. Clin. Immunol. 142, 31-37. doi:10.1016/j.clim.2011.04.005
4. Bielekova, B., Sung, M. H., Kadom, N., Simon, R., McFarland, H., and Martin, R. (2004). Expansion and functional relevance of high-avidity myelin-specific CD4+ T cells in multiple sclerosis. J. Immunol. 172, 3893-3904.
5. Bleeker, W. K., Munk, M. E., Mackus, W. J., Van Den Brakel, J. H., Pluyter, M., Glennie, M. J., et al. (2008). Estimation of dose requirements for sustained in vivo activity of a therapeutic human anti-CD20 antibody. Br. J. Haematol. 140, 303-312. doi:10.1111/j.1365-2141.2007.06916.x
6. Braud, V. M., Tomasec, P., and Wilkinson, G. W. (2002). Viral evasion of natural killer cells during human cytomegalovirus infection. Curr. Top. Microbiol. Immunol. 269, 117-129. doi:10.1007/978-3-642-59421-2_8
7. Brok, H. P., Boven, L., Van Meurs, M., Kerlero De Rosbo, N., Celebi-Paul, L., Kap, Y. S., et al. (2007). The human CMV-UL86 peptide 981-1003 shares a crossreactive T-cell epitope with the encephalitogenic MOG peptide 34-56, but lacks the capacity to induce EAE in rhesus monkeys. J. Neuroimmunol. 182, 135-152. doi:10.1016/j.jneuroim.2006.10.010
8. Brok, H. P., Uccelli, A., Kerlero De Rosbo, N., Bontrop, R. E., Roccatagliata, L., De Groot, N. G., et al. (2000). Myelin/oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis in common marmosets: the encephalitogenic T cell epitope pMOG24-36 is presented by a monomorphic MHC class II molecule. J. Immunol. 165, 1093-1101.
9. Broux, B., Pannemans, K., Zhang, X., Markovic-Plese, S., Broekmans, T., Eijnde, B. O., et al. (2012). CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. J. Autoimmun. 38, 10-19. doi:10.1016/j.jaut.2011.11.006
10. Casiraghi, C., Shanina, I., Cho, S., Freeman, M. L., Blackman, M. A., and Horwitz, M. S. (2012). Gammaherpesvirus latency accentuates EAE pathogenesis: relevance to Epstein-Barr virus and multiple sclerosis. PLoS Pathog. 8:e1002715. doi:10.1371/journal.ppat.1002715
11. Cho, Y., Ramer, J., Rivailler, P., Quink, C., Garber, R. L., Beier, D. R., et al. (2001). An Epstein-Barr-related herpesvirus from marmoset lymphomas. Proc. Natl. Acad. Sci. U.S.A. 98, 1224-1229. doi:10.1073/pnas.98.3.1224
12. Christensen, T. (2007). Human herpesviruses in MS. Int. MS J. 14, 41-47.
13. Cross, A. H., Stark, J. L., Lauber, J., Ramsbottom, M. J., and Lyons, J. A. (2006). Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J. Neuroimmunol. 180, 63-70. doi:10.1016/j.jneuroim.2006.06.029
14. Davidson, A. (2010). Targeting BAFF in autoimmunity. Curr. Opin. Immunol. 22, 732-739. doi:10.1016/j.coi.2010.09.010
15. Davis, M. M. (2008). A prescription for human immunology. Immunity 29, 835-838. doi:10.1016/j.immuni.2008.12.003
16. Doxiadis, G. G., Van Der Wiel, M. K., Brok, H. P., De Groot, N. G., Otting, N., 'T Hart, B. A., et al. (2006). Reactivation by exon shuffling of a conserved HLA-DR3-like pseudogene segment in a New World primate species. Proc. Natl. Acad. Sci. U.S.A. 103, 5864-5868. doi:10.1073/pnas.0600643103
17. Dutta, N., Gupta, A., Mazumder, D. N., and Banerjee, S. (2006). Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: implication for viral-induced immune evasion. Cancer 106, 1685-1693. doi:10.1002/cncr.21784
18. Engelhardt, B., and Kappos, L. (2008). Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener. Dis. 5, 16-22. doi:10.1159/000109933
19. Genain, C. P., Nguyen, M. H., Letvin, N. L., Pearl, R., Davis, R. L., Adelman, M., et al. (1995). Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J. Clin. Invest. 96, 2966-2974. doi:10.1172/JCI118368
20. Gran, B., Zhang, G. X., and Rostami, A. (2004). Role of the IL-12/IL-23 system in the regulation of T-cell responses in central nervous system inflammatory demyelination. Crit. Rev. Immunol. 24, 111-128. doi:10.1615/CritRevImmunol.v24.i2.20
21. Hartung, H. P., and Kieseier, B. C. (2010). Atacicept: targeting B cells in multiple sclerosis. Ther. Adv. Neurol. Disord. 3, 205-216. doi:10.1177/1756285610371146
22. Hunt, J. S. (2006). Stranger in a strange land. Immunol. Rev. 213, 36-47. doi:10.1111/j.1600-065X.2006.00436.x
23. Jagessar, S. A., Fagrouch, Z., Heijmans, N., Bauer, J., Laman, J. D., Oh, L., et al. (2013). The different clinical effects of anti-BLyS, anti-APRIL and anti-CD20 antibodies point at a critical pathogenic role of γ-herpesvirus infected B cells in the marmoset EAE model. J. Neroimmune Pharmacol. 8, 727-738. doi:10.1007/s11481-013-9448-6
24. Jagessar, S. A., Heijmans, N., Bauer, J., Blezer, E. L., Laman, J. D., Hellings, N., et al. (2012a). B-cell depletion abrogates T cell-mediated demyelination in an antibody-nondependent common marmoset experimental autoimmune encephalomyelitis model. J. Neuropathol. Exp. Neurol. 71, 716-728. doi:10.1097/NEN.0b013e3182622691
25. Jagessar, S. A., Heijmans, N., Blezer, E. L., Bauer, J., Blokhuis, J. H., Wubben, J. A., et al. (2012b). Unravelling the T-cell-mediated autoimmune attack on CNS myelin in a new primate EAE model induced with MOG34-56 peptide in incomplete adjuvant. Eur. J. Immunol. 42, 217-227. doi:10.1002/eji.201141863
26. Jagessar, S. A., Kap, Y. S., Heijmans, N., Van Driel, N., Brok, H. P. M., Blezer, E. L. A., et al. (2010). Induction of progressive demyelinating autoimmune encephalomyeitis in common marmoset monkeys using MOG34-56 peptide in incomplete Freund's adjuvant. J. Neuropathol. Exp. Neurol. 69, 372-385. doi:10.1097/NEN.0b013e3181d5d053
27. Jagessar, S. A., Smith, P. A., Blezer, E., Delarasse, C., Pham-Dinh, D., Laman, J. D., et al. (2008). Autoimmunity against myelin oligodendrocyte glycoprotein is dispensable for the initiation although essential for the progression of chronic encephalomyelitis in common marmosets. J. Neuropathol. Exp. Neurol. 67, 326-340. doi:10.1097/NEN.0b013e31816a6851
28. Jiang, H., and Chess, L. (2000). The specific regulation of immune responses by CD8+ T cells restricted by the MHC class Ib molecule, Qa-1. Annu. Rev. Immunol. 18, 185-216. doi:10.1146/annurev.immunol.18.1.185
29. Jiang, W., Lederman, M. M., Harding, C. V., and Sieg, S. F. (2011). Presentation of Soluble Antigens to CD8+ T Cells by CpG Oligodeoxynucleotide-Primed Human Naive B Cells. J. Immunol. 186, 2080-2086. doi:10.4049/jimmunol.1001869
30. Kap, Y. S., Bauer, J., Driel, N. V., Bleeker, W. K., Parren, P. W., Kooi, E. J., et al. (2011). B-cell depletion attenuates white and gray matter pathology in marmoset experimental autoimmune encephalomyelitis. J. Neuropathol. Exp. Neurol. 70, 992-1005. doi:10.1097/NEN.0b013e318234d421
31. Kap, Y. S., Smith, P., Jagessar, S. A., Remarque, E., Blezer, E., Strijkers, G. J., et al. (2008). Fast progression of recombinant human myelin/oligodendrocyte glycoprotein (MOG)-induced experimental autoimmune encephalomyelitis in marmosets is associated with the activation of MOG34-56-specific cytotoxic T cells. J. Immunol. 180, 1326-1337.
32. Kap, Y. S., Van Driel, N., Blezer, E., Parren, P. W., Bleeker, W. K., Laman, J. D., et al. (2010). Late B cell depletion with a human anti-human CD20 IgG1kappa monoclonal antibody halts the development of experimental autoimmune encephalomyelitis in marmosets. J. Immunol. 185, 3990-4003. doi:10.4049/jimmunol.1001393
33. Khan, G., Miyashita, E. M., Yang, B., Babcock, G. J., and Thorley-Lawson, D. A. (1996). Is EBV persistence in vivo a model for B cell homeostasis?. Immunity 5, 173-179. doi:10.1016/S1074-7613(00)80493-8
34. Klotz, L., Meuth, S. G., and Wiendl, H. (2012). Immune mechanisms of new therapeutic strategies in multiple sclerosis-A focus on alemtuzumab. Clin. Immunol. 142, 25-30. doi:10.1016/j.clim.2011.04.006
35. Krishnamoorthy, G., Holz, A., and Wekerle, H. (2007). Experimental models of spontaneous autoimmune disease in the central nervous system. J. Mol. Med. 85, 1161-1173. doi:10.1007/s00109-007-0218-x
36. Krumbholz, M., Derfuss, T., Hohlfeld, R., and Meinl, E. (2012). B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat. Rev. Neurol. 8, 613-623. doi:10.1038/nrneurol.2012.203
37. Lanzavecchia, A., and Bove, S. (1985). Specific B lymphocytes efficiently pick up, process and present antigen to T cells. Behring Inst. Mitt. 77, 82-87.
38. Leishman, A. J., Naidenko, O. V., Attinger, A., Koning, F., Lena, C. J., Xiong, Y., et al. (2001). T cell responses modulated through interaction between CD8alphaalpha and the nonclassical MHC class I molecule, TL. Science 294, 1936-1939. doi:10.1126/science.1063564
39. Lindsey, J. W., Hodgkinson, S., Mehta, R., Mitchell, D., Enzmann, D., and Steinman, L. (1994). Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis. Ann. Neurol. 36, 183-189. doi:10.1002/ana.410360210
40. Liu, Z., and Davidson, A. (2011). BAFF and selection of autoreactive B cells. Trends Immunol. 32, 388-394. doi:10.1016/j.it.2011.06.004
41. Logtenberg, T., Kroon, A., Gmelig-Meyling, F. H., and Ballieux, R. E. (1986). Production of anti-thyroglobulin antibody by blood lymphocytes from patients with autoimmune thyroiditis, induced by the insolubilized autoantigen. J. Immunol. 136, 1236-1240.
42. Lunemann, J. D., Kamradt, T., Martin, R., and Munz, C. (2007). Epstein-Barr virus: environmental trigger of multiple sclerosis? J. Virol. 81, 6777-6784. doi:10.1128/JVI.00153-07
43. Lunemann, J. D., and Munz, C. (2009). EBV in MS: guilty by association? Trends Immunol. 30, 243-248. doi:10.1016/j.it
44. Madakamutil, L. T., Christen, U., Lena, C. J., Wang-Zhu, Y., Attinger, A., Sundarrajan, M., et al. (2004). CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors. Science 304, 590-593. doi:10.1126/science.1092316
45. Matsushita, T., Yanaba, K., Bouaziz, J. D., Fujimoto, M., and Tedder, T. F. (2008). Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J. Clin. Invest. 118, 3420-3430. doi:10.1172/JCI36030
46. Mazzarino, P., Pietra, G., Vacca, P., Falco, M., Colau, D., Coulie, P., et al. (2005). Identification of effector-memory CMV-specific T lymphocytes that kill CMV-infected target cells in an HLA-E-restricted fashion. Eur. J. Immunol. 35, 3240-3247. doi:10.1002/eji.200535343
47. McFarland, H. I., Lobito, A. A., Johnson, M. M., Nyswaner, J. T., Frank, J. A., Palardy, G. R., et al. (1999). Determinant spreading associated with demyelination in a nonhuman primate model of multiple sclerosis. J. Immunol. 162, 2384-2390.
48. Menge, T., Von Budingen, H. C., Lalive, P. H., and Genain, C. P. (2007). Relevant antibody subsets against MOG recognize conformational epitopes exclusively exposed in solid-phase ELISA. Eur. J. Immunol. 37, 3229-3239. doi:10.1002/eji.200737249
49. Moretta, L., Romagnani, C., Pietra, G., Moretta, A., and Mingari, M. C. (2003). NK-CTLs, a novel HLA-E-restricted T-cell subset. Trends Immunol. 24, 136-143. doi:10.1016/S1471-4906(03)00031-0
50. Oliver, A. R., Lyon, G. M., and Ruddle, N. H. (2003). Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J. Immunol. 171, 462-468.
51. Pender, M. P. (2011). The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist 17, 351-367. doi:10.1177/1073858410381531
52. Pollinger, B., Krishnamoorthy, G., Berer, K., Lassmann, H., Bosl, M. R., Dunn, R., et al. (2009). Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 206, 1303-1316. doi:10.1084/jem.20090299
53. Quintans, J., and Lefkovits, I. (1974). Clones of antibody-forming cells in pokeweed mitogen stimulated microcultures. II. Estimation of the frequency of precursor cells and the average clone size. Eur. J. Immunol. 4, 617-621. doi:10.1002/eji.1830040907
54. Racadot, E., Rumbach, L., Bataillard, M., Galmiche, J., Henlin, J. L., Truttmann, M., et al. (1993). Treatment of multiple sclerosis with anti-CD4 monoclonal antibody. A preliminary report on B-F5 in 21 patients. J. Autoimmun. 6, 771-786. doi:10.1006/jaut.1993.1063
55. Ransohoff, R. M. (2006). EAE: pitfalls outweigh virtues of screening potential treatments for multiple sclerosis. Trends Immunol. 27, 167-168. doi:10.1016/j.it.2006.02.007
56. Ransohoff, R. M. (2012). Animal models of multiple sclerosis: the good, the bad and the bottom line. Nat. Neurosci. 15, 1074-1077. doi:10.1038/nn.3168
57. Rickert, R. C., Jellusova, J., and Miletic, A. V. (2011). Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol. Rev. 244, 115-133. doi:10.1111/j.1600-065X.2011.01067.x
58. Sachs, D. H. (2003). Tolerance: of mice and men. J. Clin. Invest. 111, 1819-1821. doi:10.1172/JCI18926
59. Scotet, E., Peyrat, M. A., Saulquin, X., Retiere, C., Couedel, C., Davodeau, F., et al. (1999). Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes. Eur. J. Immunol. 29, 973-985. doi:10.1002/(SICI)1521-4141(199903)29:03<973::AID-IMMU973>;3.3.CO;2-G
60. Segal, B. M., Constantinescu, C. S., Raychaudhuri, A., Kim, L., Fidelus-Gort, R., and Kasper, L. H. (2008). Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol. 7, 796-804. doi:10.1016/S1474-4422(08)70173-X
61. Sospedra, M., and Martin, R. (2005). Immunology of multiple sclerosis. Annu. Rev. Immunol. 23, 683-747. doi:10.1146/annurev.immunol.23.021704.115707
62. Sriram, S., and Steiner, I. (2005). Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann. Neurol. 58, 939-945. doi:10.1002/ana.20743
63. Steinman, L. (2005). Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4, 510-518. doi:10.1038/nrd1752
64. Steinman, L., and Zamvil, S. S. (2006). How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann. Neurol. 60, 12-21. doi:10.1002/ana.20913
65. Sylwester, A. W., Mitchell, B. L., Edgar, J. B., Taormina, C., Pelte, C., Ruchti, F., et al. (2005). Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J. Exp. Med. 202, 673-685. doi:10.1084/jem.20050882
66. van Oosten, B. W., Barkhof, F., Truyen, L., Boringa, J. B., Bertelsmann, F. W., Von Blomberg, B. M., et al. (1996). Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47, 1531-1534. doi:10.1212/WNL.47.6.1531
67. Villoslada, P., Abel, K., Heald, N., Goertsches, R., Hauser, S. L., and Genain, C. P. (2001). Frequency, heterogeneity and encephalitogenicity of T cells specific for myelin oligodendrocyte glycoprotein in naive outbred primates. Eur. J. Immunol. 31, 2942-2950. doi:10.1002/1521-4141(2001010)31:10<2942::AID-IMMU2942>;3.0.CO;2-M
68. Weber, M. S., Prod'homme, T., Patarroyo, J. C., Molnarfi, N., Karnezis, T., Lehmann-Horn, K., et al. (2010). B-cell activation influences T-cell polarization and outcome of anti-CD20 B-cell depletion in central nervous system autoimmunity. Ann. Neurol. 68, 369-383. doi:10.1002/ana.22081
69. Wischhusen, J., Waschbisch, A., and Wiendl, H. (2007). Immune-refractory cancers and their little helpers - an extended role for immunetolerogenic MHC molecules HLA-G and HLA-E? Semin. Cancer Biol. 17, 459-468. doi:10.1016/j.semcancer.2007.07.005
70. Zaguia, F., Saikali, P., Ludwin, S., Newcombe, J., Beauseigle, D., McCrea, E., et al. (2013). Cytotoxic NKG2C+ CD4 T cells target oligodendrocytes in multiple sclerosis. J. Immunol. 8, 2013. doi:10.4049/jimmunol.1202725
71. 'T Hart, B. A., and Bajramovic, J. (2008). Non-human primate models of multiple sclerosis. Drug Discov. Today 5, 97-104. doi:10.1016/j.ddmod.2008.06.001
72. 'T Hart, B. A., Brok, H. P., Remarque, E., Benson, J., Treacy, G., Amor, S., et al. (2005). Suppression of ongoing disease in a nonhuman primate model of multiple sclerosis by a human-anti-human IL-12p40 antibody. J. Immunol. 175, 4761-4768.
73. 'T Hart, B. A., Chalan, P., Koopman, G., and Boots, A. M. H. (2013). Chronic autoimmune-mediated inflammation, a senescent immune response to injury. Drug Discov. Today 18, 372-379. doi:10.1016/j.drudis.2012.11.010
74. 'T Hart, B. A., Gran, B., and Weissert, R. (2011). EAE: imperfect but useful models of multiple sclerosis. Trends. Mol. Med. 17, 119-125. doi:10.1016/j.molmed.2010.11.006
75. 'T Hart, B. A., Hintzen, R. Q., and Laman, J. D. (2009). Multiple sclerosis - a response-to-damage model. Trends. Mol. Med. 15, 235-244. doi:10.1016/j.molmed.2009.04.001
76. 'T Hart, B. A., Laman, J. D., Bauer, J., Blezer, E. D., Van Kooyk, Y., and Hintzen, R. Q. (2004). Modelling of multiple sclerosis: lessons learned in a non-human primate. Lancet Neurol. 3, 589-597. doi:10.1016/S1474-4422(04)00879-8
77. 'T Hart, B. A., and Massacesi, L. (2009). Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J. Neuropathol. Exp. Neurol. 68, 341-355. doi:10.1097/NEN.0b013e31819f1d24